SCHEMBL5769828

SCHEMBL5769828

COc1c2ccccc2cc2c1c1c(C(=O)O)cccc1n2Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 3/20 0.47
FABP4 P15090 3/20 0.46
NOTUM Q6P988 1/20 0.44
EDNRB P24530 1/20 0.44
EDNRA P25101 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PLA2G2A P14555 3/20 0.42
PLA2G10 O15496 1/20 0.42
PLA2G1B P04054 1/20 0.42
PLA2G2E Q9NZK7 1/20 0.42
PLA2G2D Q9UNK4 1/20 0.42
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
KMT2A Q03164 1/20 0.42
APEX1 P27695 1/20 0.42
MCL1 Q07820 2/20 0.41
BAD Q92934 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772908 0.85 CCR2 (0.47) CCR2FABP4NOTUMKDM4EALDH1A1
SCHEMBL5768372 0.80 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D
SCHEMBL5770181 0.80 FABP4 (0.48) CCR2FABP4NOTUMPLA2G2A
SCHEMBL8180702 0.78 CYP19A1 (0.59) CCR2FABP4NOTUMKDM4EALDH1A1
SCHEMBL5771308 0.76 PLA2G10 (0.43) CCR2FABP4KDM4EALDH1A1GAA
SCHEMBL5769799 0.74 PARP1 (0.50) KDM4EALDH1A1HSD17B10CDC25B
SCHEMBL5018089 0.72 CCR2 (0.50) CCR2FABP4NOTUMEDNRBEDNRA
SCHEMBL9538638 0.71 CCR2 (0.77) CCR2EDNRBEDNRAKDM4EALDH1A1
SCHEMBL6688548 0.70 PLA2G2A (0.46) KDM4EPLA2G2APLA2G10TP53
SCHEMBL6695139 0.70 PLA2G2A (0.51) EDNRBEDNRAPLA2G2APLA2G10MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349836-B1 TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS LILLY CO ELI (US) 2006-06-14 EP disclosed
US-6992100-B2 sPLA2 inhibitors ELI LILLY AND COMPANY (US) 2006-01-31 US disclosed
US-20040092543-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092543-A1 Novel spla2 inhibitors PLA2G12A, PLAAT2, SPINT2 CCR2 2147/4885FABP4 261/4885NOTUM 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.